Covid-19 creates uncertainty for Zealand Pharma drug against short bowel syndrome

Zealand Pharma's clinical development is running smoothly and the firm has sent a new drug candidate to clinic. Reversely, the resurgence of the Covid-19 pandemic has caused uncertainty regarding the time schedule for the firm's phase III drug Glepaglutide.
Zealand Pharma's CEO Emanuel Dulac. | Photo: Stine Bidstrup/ERH
Zealand Pharma's CEO Emanuel Dulac. | Photo: Stine Bidstrup/ERH
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

As a biotech firm, Zealand Pharma's first priority during Covid-19 has been to ensure that its research and development program could continue with as few alterations as possible.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading